Search results (13)
« Back to NewsPhase I trial begins of new vaccine against the Plague
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
COVID-19 Clinical Trials Vaccinology
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
COVID-19 Clinical Trials Vaccinology
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
First trial participants vaccinated with Oxford COVID-19 variant vaccine
28 June 2021
COVID-19 Clinical Trials Vaccinology
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
Alternating vaccines trial expands to include two additional vaccines
14 April 2021
COVID-19 Clinical Trials Vaccinology
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Oxford leads first trial investigating dosing with alternating vaccines
4 February 2021
COVID-19 Clinical Trials Vaccinology
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
15 June 2020
COVID-19 Clinical Trials Vaccinology
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
Oxford COVID-19 vaccine to begin phase II/III human trials
22 May 2020
COVID-19 Clinical Trials Vaccinology
Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
Blueprint Magazine features paediatric research
13 February 2019
Children's Health Clinical Trials Neuroimaging Publication
In the latest issue of the Blueprint, Shaunna Latchman meets Professor of Paediatric Neuroimaging, Rebeccah Slater to discuss the Paediatric Neuroimaging Group and find out why a gentle touch really does goes a long way.
Is morphine an effective and safe analgesic for premature babies?
7 December 2018
Clinical Trials Neuroimaging Research
The Lancet has published the results of the Procedural Pain in Premature Infants (Poppi) study, ran by the Paediatric Neuroimaging Group and co-ordinated by the National Perinatal Epidemiology Unit (Clinical Trials Unit).
Pregnant women invited to take part in pioneering diabetes prevention research
16 July 2018
Clinical Trials Parents & Carers Recruitment Research
Dr Matthew Snape leads a study investigating if giving small amounts of oral insulin to babies can prevent type 1 diabetes, thus allowing mothers to protect their children from injecting insulin.
International Clinical Trials Day at the Children's Hospital
25 May 2018
Clinical Trials Public Engagement Vaccinology
Why do we celebrate the International Clinical Trials Day?
Oxford Vaccine Group leads meningitis vaccine trial for teenagers
28 March 2018
Clinical Trials Recruitment Research Vaccinology
Researchers are working with schools around the county to find 24,000 volunteers aged 16 to 18 years to take part in the Be on the TEAM (Teenagers Against Meningitis) trial, led by the Oxford Vaccine Group at the Oxford University's Paediatrics Department with funding and support from the National Institute for Health Research (NIHR).